Your browser doesn't support javascript.
Anti-spike antibody response to natural SARS-CoV-2 infection in the general population.
Wei, Jia; Matthews, Philippa C; Stoesser, Nicole; Maddox, Thomas; Lorenzi, Luke; Studley, Ruth; Bell, John I; Newton, John N; Farrar, Jeremy; Diamond, Ian; Rourke, Emma; Howarth, Alison; Marsden, Brian D; Hoosdally, Sarah; Jones, E Yvonne; Stuart, David I; Crook, Derrick W; Peto, Tim E A; Pouwels, Koen B; Walker, A Sarah; Eyre, David W.
  • Wei J; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Matthews PC; Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Stoesser N; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Maddox T; Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.
  • Lorenzi L; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Studley R; Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.
  • Bell JI; The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.
  • Newton JN; The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Farrar J; Office for National Statistics, Newport, UK.
  • Diamond I; Office for National Statistics, Newport, UK.
  • Rourke E; Office for National Statistics, Newport, UK.
  • Howarth A; Office of the Regius Professor of Medicine, University of Oxford, Oxford, UK.
  • Marsden BD; Health Improvement Directorate, Public Health England, London, UK.
  • Hoosdally S; Wellcome Trust, London, UK.
  • Jones EY; Office for National Statistics, Newport, UK.
  • Stuart DI; Office for National Statistics, Newport, UK.
  • Crook DW; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Peto TEA; The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Pouwels KB; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Walker AS; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
  • Eyre DW; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Nat Commun ; 12(1): 6250, 2021 10 29.
Article in English | MEDLINE | ID: covidwho-1493099
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Understanding the trajectory, duration, and determinants of antibody responses after SARS-CoV-2 infection can inform subsequent protection and risk of reinfection, however large-scale representative studies are limited. Here we estimated antibody response after SARS-CoV-2 infection in the general population using representative data from 7,256 United Kingdom COVID-19 infection survey participants who had positive swab SARS-CoV-2 PCR tests from 26-April-2020 to 14-June-2021. A latent class model classified 24% of participants as 'non-responders' not developing anti-spike antibodies, who were older, had higher SARS-CoV-2 cycle threshold values during infection (i.e. lower viral burden), and less frequently reported any symptoms. Among those who seroconverted, using Bayesian linear mixed models, the estimated anti-spike IgG peak level was 7.3-fold higher than the level previously associated with 50% protection against reinfection, with higher peak levels in older participants and those of non-white ethnicity. The estimated anti-spike IgG half-life was 184 days, being longer in females and those of white ethnicity. We estimated antibody levels associated with protection against reinfection likely last 1.5-2 years on average, with levels associated with protection from severe infection present for several years. These estimates could inform planning for vaccination booster strategies.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral / Antibody Formation Type of study: Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-26479-2

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral / Antibody Formation Type of study: Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-26479-2